Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
Watch CNBC’s full interview with Oppenheimer’s Jason Helfstein
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Jason Helfstein, Oppenheimer head of internet research, joins ‘Power Lunch’ to discuss positive expectations for Netflix’s earnings results, the cancelation reduction force of Netflix’s new ad tier, and Amazon’s adoption of live sports programming. 05:29 Tue, Oct 18 20222:56 PM EDT
A Suze retrospective
Classic clips from 13 years of The Suze Orman Show.
Financial impact from Boeing’s Max-9 blowout is still limited, says Morningstar’s Nicolas Owens
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Nicolas Owens, Morningstar, joins ‘Fast Money’ to explain why he believes the financial impact of Boeing’s Max-9 incident won’t be a long term concern for the stock.
Wedbush Securities’ Dan Ives says he would buy Lyft and Uber
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Closing Bell Dan Ives from Wedbush Securities joins ‘Closing Bell’ to discuss ride-sharing companies Lyft and Uber. 02:42 Tue, May 3 20224:19 PM EDT
Barclay’s Jason Goldberg previews big bank earnings: Here’s what to expect
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Jason Goldberg, Barclays senior equity analyst, joins ‘Squawk Box’ to preview Friday’s big bank earnings results, what it means for the banking sector at large, and more. 04:23 Thu, Jan 11 20248:10 AM EST
Did you know Alcoa helped make all this?
Alcoa is an integral part of consumers’ lives whether they know it or not.
